Triple-Drug attack on rare lymphoma shows early promise

NCT ID NCT03523975

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing whether a combination of three drugs—venetoclax, lenalidomide, and rituximab—is safe and effective for people with untreated mantle cell lymphoma, a rare blood cancer. About 28 adults will take these pills and infusions over several months. The goal is to find the best dose and see how many patients achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax, lenalidomide, and rituximab (drug combination)
What this could lead to: If successful, this could offer a new, effective first-line treatment option for mantle cell lymphoma, potentially improving remission rates.
What could go wrong: This is an early-phase trial with only 28 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it's not yet known if it works better than current standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

City of Hope Medical center
RECRUITING

Duarte, California, 91010, United States
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States

Contact Email: •••••@•••••
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.